TrialNature medicine2021

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

Tien Dam et al.PubMed ↗Publisher ↗

No numbers read from the abstract.